Propanc Biopharma, Inc. · NASDAQ:PPCB
Propanc Biopharma — Investor Presentation (February 2019)
25 slides from Propanc Biopharma's investor presentation, Feb 12, 2019
Slide 1: Developing a Novel Approach to Treat Metastatic Solid Tumors
Developing a Novel Approach to (@® Propanc _ Treat Metastatic Solid Tumors Bopha inc: James Nathanielsz, Chief Executive Officer February 12, 2019
Slide 2: Forward Looking Statement
Forward Looking Statement ‘The information in this presentation is provided to you by Propanc Biopharma, Inc. (the “Company”) solely for informational purposes and is not an offer to buy or ‘ell, oa solicitation of an offer to buy or sell, any security or instrument of the Company, orto participate
Slide 3: Here's how it works...
Here’s how it works... @ Propane Approximately 80% of cancers are from solid tumors and metastasis is the main cause of patient death. Cancer stem cells are resistant to standard treatments, remain dormant for long periods, then migrate to other organs, triggering explosive tumor growth, causing pat
Slide 4: Biopharmaceutical company developing new cancer treatments
Biopharmaceutical company developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. Proenzyme therapy approach based on 100 years of enzyme use. 40 years of combined pharma/biotech experience. 80 years of combined scientific research expertise. Robust p
Slide 5: Ye) J
Ye) J /Chymotrypsinogen LV. injection
Slide 6: Pancreatic Enzyme Therapy
Pancreatic Enzyme Therapy Enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. * Over 100 years ago, Professor John Beard proposed that siianiscacat pancreatic enzymes represents © trypsinogen : Chymetyprinegen the body’s primary defense ioc ts and amylase
Slide 7: Mixture of proenzymes from bovine pancreas
Mixture of 2 proenzymes from bovine pancreas. Synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include ovarian and colorectal cancers. Efficacy also shown in pancreatic, kidney, breast, brain, prostate, lung, liver, uterine and skin cancers.
Slide 8: PRP has the potential to convert cancerous cells back into normal cells
PRP has the potential to convert cancerous cells back into normal cells. Tumor cells return to the normal pathways of a differentiated cell. Post treatment evidence shows that colorectal and pancreatic cancer cells return to normal cell behavior. Caco? cells untreated (a) and treat (o- 4). In (b) nu
Slide 9: PRP Compassionate Patient Treatment
PRP Compassionate Patient Treatment Results Cancer Type Responders Vs Patients* ¢ 46 terminal patients administered . . a Ovarian Cancer 4/6 suppository formulation containing - t . & chymotrypsinogen Pancreatic cancer 3/4 rypsinogen v yp gen. Gastric cancer 2/2 e No severe, or even serious adverse
Slide 10: A New Frontier
A New Frontier Anti-Cancer Stem Cell Therapy ® Propanc aeeen
Slide 11: Kill replicating cancer cells, but deep inside tumors are cells that develop resistance
Kill replicating cancer cells, but deep inside tumors are cells that develop resistance, called cancer stem cells. Can remain dormant for long periods. Migrate to other organs spreading the cancer.
Slide 12: PRP Reverses Epithelial to Mesenchymal Transition (EMT)
PRP Reverses Epithelial to Mesencyhmal Transition (EMT) EMT INTRACELLULAR SIGNALLING NETWORKS: PRP PROMOTES Proteins responsible for cell fo cell contact f ‘ore expressed METASTASIS jt \ J PRP HAS ANTI-CANCER EFFECTS, BLOCKING TUMOR GROWTH AND ‘AGGRESSIVE DISSEMINATION ® Propanc propane-comn 12
Slide 13: Cancer stem cells die naturally by reprogramming
* Cancer stem cells die B naturally by ae BxPcs 14 reprogramming the on cancer stem cell to 1 reduce malignancy and 5 a i | I * invasiveness. 3 ey * PRP promotes the Ff al expression of E-cadherin 3 ous AIMENTINE and decreases expression 2 * -A2TEO of N-cadherin & vimentin 2 * mesenchymal markers. ™
Slide 14: PRP Offers Paradigm Shift in Standard of Care
PRP Offers Paradigm Shift in Standard of Care * No adverse events observed. ° Since PRP does not target replicating cells, it is unlikely to affect healthy cells and will suppress undesirable effects from cancer. ° PRP regulates expression of genes that triggers dominant pathways that are turned on
Slide 15: Corporate Strategy
Corporate Strategy Future Landscape @ Propanc OTCQB: PPCB ieee
Slide 16: Competitor Analysis
Competitor Analysis Company Name Overview Stemline therapies (IL-3), small molecule inhibitor of XPO1 and an immunotherapy, with a focus on additional 24 generation IL-3 targeted compounds OMED | $25.6 Currently 3 therapeutic candidates in clinical 3 in Phase | OncoMed development targeting cancer s
Slide 17: Executive Leadership with Significant Scientific and Clinical Expertise
Executive Leadership with Significant Scientific and Clinical Expertise Mr James Nathanielsz Chief Executive Officer Director & C.E.O, Oct ‘07. 20 yrs. experience in R&D, Manufacturing & Distribution, including 10 yrs. in oncology Bachelor of Applied Science (Biochemistry/ Applied Chemistry) & Maste
Slide 18: Medical and Scientific Advisory Board
Medical and Scientific Advisory Board Professor John Smyth Univ. of Edinburgh Professor Emeritus Medical Oncology & Honorary Assistant Principal Cancer Research Development, Univ. of Edinburgh. Chair, Expert Advisory Group for Oncology & Hematology for the Commission of Medicines. Serves on the Expe
Slide 19: International R&D Partnerships
International R&D Partnerships UNIVERSITY OF Joint IP ownership and Commercialization BATH P ——— Agreement. Joint research collaboration: ® Universidad de Jaén Universidad de Granada « FIBA Drug discovery oncology program New compound screening Translational research Clinical development Process dev
Slide 20: PRP Well-Positioned to Start First-In Human Study for Solid Tumors
PRP Well-Positioned to Start First-In Human Study for Solid Tumors * Scientific advice meetings with MHRA (UK), Apr 2016 and Mar 2018, for PRP, completed. ° Preclinical pharmacology and safety toxicology studies completed. * Orphan Drug Designation Status received from the FDA for the treatment of p
Slide 21: PRP Timelines
PRP Timelines 2019/20 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan (CTA Preparation Investigational Medicinal Product Dossier (IMPD) ‘Study Protocol (SP) cTA Investigator's Brochure (IB) Review CTACompilation hr CTASubmission CTA Approval Study Preparation CRO Selection & Contracts Analytical
Slide 22: Investment Opportunity
Investment Opportunity ° Seeking $4M for IMP Manufacture and submission of Clinical Trial Application (CTA) for PRP, Phase I, FIH study. * Initiate POP1 drug discovery program. * Follow on round of $10M for early stage clinical development of PRP. ° Evaluating Phase | & Il sites in AUS, attractive 4
Slide 23: Market Opportunity
Market Opportunity * 80% of ALL cancers are % Future Combined Markets in 2020, solid tumors: GBI Research ($$Billions) — Initially target pancreatic, ovarian & colorectal tumors. m colorectal — 780,702 global deaths, combined, in 2012 (WHO). pancreatic — $14B combined market segment by 2020 (GBI Res
Slide 24: Partnering/ Licensing Strategy
Partnering/ Licensing Strategy * Launched awareness/marketing outreach campaign: * Top 20 international oncology companies. * Strong encouragement for innovative approach. * Definite interest in product, positive response, no significant concerns. * Data from FIH studies to generate further discussi
Slide 25: Thank You!
Thank You! February 12, 2019 James Nathanielsz Chief Executive Officer +61-414-835-002 j.nathanielsz@propanc.com @) Propanc 302/6 Butler Street, Camberwell, Victoria, 3124, AUSTRALIA Biopharma, Inc. propanc.com
Propanc Biopharma — Investor Presentation (February 2019) on 6ix